Top

Published in:

01-07-2018 | Invited Review

Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients

Authors: Mihai Dorin Vartolomei, Shoji Kimura, Matteo Ferro, Liliana Vartolomei, Beat Foerster, Mohammad Abufaraj, Shahrokh F. Shariat

Published in: World Journal of Urology | Issue 7/2018

Abstract

Background

Preoperative blood-based inflammatory biomarkers have been suggested to improve staging and prognostication in patients with upper-tract urothelial carcinoma (UTUC). Neutrophil-to-lymphocyte ratio (NLR) is the most studied blood-based biomarker. NLR is an indicator of systemic inflammation and has been shown to be associated with a poor prognosis in various malignancies. The aim of this study was to analyze the current evidence regarding the prognostic significance of preoperative NLR in patients undergoing radical nephroureterectomy (RNU) for UTUC to assess its prognostic potential.

Materials and methods

A systematic search of Web of Science, Medline/PubMed and Cochrane library was performed on the 1st of October, 2017. Studies were deemed eligible if they compared patients with high NLR before surgical treatment for UTUC to patients with low NLR to determine its predictive value for survival using multivariable logistic regression analysis. We performed a formal meta-analysis for cancer-specific survival (CSS), recurrence-free survival (RFS) and overall survival (OS).

Results

Nine studies including a total of 4385 patients assessing the importance of NLR were included in this meta-analysis. The cut-off NLR varied in the eligible studies ranging from 2 to 3. Increased pretreatment NLR predicted OS (pooled HR 1.64 95% CI; 1.23–2.17), RFS (pooled HR 1.60 95% CI; 1.16–2.20) and CSS (pooled HR 1.73 95% CI; 1.23–2.44) in multivariable analyses.

Conclusion

In this meta-analysis, preoperative blood-based NLR is associated with worse prognosis in patients who underwent RNU for UTUC. NLR could be used to improve clinical decision making regarding RNU vs. kidney-sparing surgery, extent of lymphadenectomy, perioperative systemic therapy and follow-up schedule.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Rouprêt M, Babjuk M, Compérat E et al (2017) European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. https://doi.org/10.1016/j.eururo.2017.07.036 CrossRefPubMed

Eylert MF, Hounsome L, Verne J et al (2013) Prognosis is deteriorating for upper tract urothelial cancer: data for England 1985–2010. BJU Int 112:E107–E113. https://doi.org/10.1111/bju.12025 CrossRefPubMed

Raman JD, Messer J, Sielatycki JA, Hollenbeak CS (2011) Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int 107:1059–1064. https://doi.org/10.1111/j.1464-410X.2010.09675.x CrossRefPubMed

Cha EK, Shariat SF, Kormaksson M et al (2012) Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 61:818–825. https://doi.org/10.1016/j.eururo.2012.01.021 CrossRefPubMed

Rink M, Sjoberg D, Comploj E et al (2012) Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 19:4337–4344. https://doi.org/10.1245/s10434-012-2499-8 CrossRefPubMedPubMedCentral

Rink M, Xylinas E, Trinh Q-D et al (2013) Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU Int 112:623–637. https://doi.org/10.1111/bju.12014 CrossRefPubMed

Ploussard G, Xylinas E, Lotan Y et al (2015) Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol 67:803–812. https://doi.org/10.1016/j.eururo.2014.08.003 CrossRefPubMed

Mathieu R, Bensalah K, Lucca I et al (2015) Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol 4:261–272. https://doi.org/10.3978/j.issn.2223-4683.2015.05.01 PubMedPubMedCentralCrossRef

10.

Chromecki TF, Cha EK, Fajkovic H et al (2012) The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253. https://doi.org/10.1016/j.eururo.2011.09.017 CrossRefPubMed

11.

Favaretto RL, Shariat SF, Chade DC et al (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58:574–580. https://doi.org/10.1016/j.eururo.2010.07.003 CrossRefPubMedPubMedCentral

12.

Raman JD, Ng CK, Scherr DS et al (2010) Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 57:1072–1079. https://doi.org/10.1016/j.eururo.2009.07.002 CrossRefPubMed

13.

Roscigno M, Shariat SF, Margulis V et al (2009) The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol 56:512–518. https://doi.org/10.1016/j.eururo.2009.06.004 CrossRefPubMed

14.

Roscigno M, Shariat SF, Margulis V et al (2009) Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 181:2482–2489. https://doi.org/10.1016/j.juro.2009.02.021 CrossRefPubMed

15.

Remzi M, Haitel A, Margulis V et al (2009) Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 103:307–311. https://doi.org/10.1111/j.1464-410X.2008.08003.x CrossRefPubMed

16.

Zigeuner R, Shariat SF, Margulis V et al (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57:575–581. https://doi.org/10.1016/j.eururo.2009.11.035 CrossRefPubMed

17.

Novara G, Matsumoto K, Kassouf W et al (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57:1064–1071. https://doi.org/10.1016/j.eururo.2009.12.029 CrossRefPubMed

18.

Xylinas E, Kluth L, Mangal S et al (2013) Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. World J Urol 31:31–36. https://doi.org/10.1007/s00345-012-0947-5 CrossRefPubMed

19.

Mbeutcha A, Shariat SF, Rieken M et al (2016) Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol 34:483-e17–483-e24. https://doi.org/10.1016/j.urolonc.2016.05.013 CrossRef

20.

Diakos CI, Charles KA, McMillan DC, Clarke SJ (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15:e493–e503. https://doi.org/10.1016/S1470-2045(14)70263-3 CrossRefPubMed

21.

Mbeutcha A, Rouprêt M, Kamat AM et al (2017) Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol 35:337–353. https://doi.org/10.1007/s00345-016-1826-2 CrossRefPubMed

22.

Mathieu R, Vartolomei MD, Mbeutcha A et al (2016) Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. Minerva Urol E Nefrol Ital J Urol Nephrol 68:381–395

23.

Yin X, Xiao Y, Li F et al (2016) Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore) 95:e2544. https://doi.org/10.1097/MD.0000000000002544 CrossRef

24.

Marchioni M, Cindolo L, Autorino R et al (2017) High neutrophil-to-lymphocyte ratio as prognostic factor in patients affected by upper tract urothelial cancer: a systematic review and meta-analysis. Clin Genitourin Cancer 15(343–349):e1. https://doi.org/10.1016/j.clgc.2016.12.027 CrossRef

25.

Matsumoto K, Novara G, Gupta A et al (2011) Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 108:E304–E309. https://doi.org/10.1111/j.1464-410X.2011.10188.x CrossRefPubMed

26.

Moher D, Liberati A, Tetzlaff J et al (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg Lond Engl 8:336–341. https://doi.org/10.1016/j.ijsu.2010.02.007 CrossRef

27.

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm, Accessed 3 Oct 2017

28.

Sung HH, Jeon HG, Jeong BC et al (2015) Clinical significance of prognosis using the neutrophil-lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Bju Int 115:587–594. https://doi.org/10.1111/bju.12846 CrossRefPubMed

29.

Azuma T, Matayoshi Y, Odani K et al (2013) Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer 11:337–341. https://doi.org/10.1016/j.clgc.2013.04.003 CrossRefPubMed

30.

Dalpiaz O, Ehrlich GC, Mannweiler S et al (2014) Validation of pretreatment neutrophil–lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int 114:334–339. https://doi.org/10.1111/bju.12441 PubMedCrossRef

31.

Luo H-L, Chen Y-T, Chuang Y-C et al (2014) Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome. BJU Int 113:E144–E149. https://doi.org/10.1111/bju.12582 CrossRefPubMed

32.

Tanaka N, Kikuchi E, Kanao K et al (2014) A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy. Ann Surg Oncol 21:4041–4048. https://doi.org/10.1245/s10434-014-3830-3 CrossRefPubMed

33.

Cheng Y-C, Huang C-N, Wu W-J et al (2016) The prognostic significance of inflammation-associated blood cell markers in patients with upper tract urothelial carcinoma. Ann Surg Oncol 23:343–351. https://doi.org/10.1245/s10434-015-4781-z CrossRefPubMed

34.

Song X, Zhang G-M, Ma X-C et al (2016) Comparison of preoperative neutrophil–lymphocyte, lymphocyte–monocyte, and platelet–lymphocyte ratios in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy. OncoTargets Ther 9:1399–1407. https://doi.org/10.2147/OTT.S97520 CrossRef

35.

Vartolomei MD, Mathieu R, Margulis V et al (2017) Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol 35:121–130. https://doi.org/10.1007/s00345-016-1848-9 CrossRefPubMed

36.

Huang J, Yuan Y, Wang Y et al (2017) Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Urol Oncol. https://doi.org/10.1016/j.urolonc.2017.07.028 CrossRefPubMed

37.

Altan M, Haberal HB, Akdogan B, Ozen H (2017) A critical prognostic analysis of neutrophil–lymphocyte ratio for patients undergoing nephroureterectomy due to upper urinary tract urothelial carcinoma. Int J Clin Oncol. https://doi.org/10.1007/s10147-017-1150-x PubMedCrossRef

38.

Favaretto RL, Shariat SF, Savage C et al (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77–82. https://doi.org/10.1111/j.1464-410X.2011.10288.x CrossRefPubMed

39.

Kishimoto N, Takao T, Kuribayashi S et al (2016) The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Int J Clin Oncol. https://doi.org/10.1007/s10147-016-1040-7 PubMedCrossRef

40.

Kang M, Jeong CW, Kwak C et al (2017) Prognostic role of neutrophil-to-lymphocyte ratio-based markers during pre- and postadjuvant chemotherapy in patients with advanced urothelial carcinoma of upper urinary tract. Clin Genitourin Cancer 15:E633–E643. https://doi.org/10.1016/j.clgc.2017.01.003 CrossRefPubMed

41.

Tang X, Du P, Yang Y (2017) The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis. Int J Clin Oncol 22:817–825. https://doi.org/10.1007/s10147-017-1171-5 CrossRefPubMed

42.

Marchioni M, Primiceri G, Ingrosso M et al (2016) The clinical use of the neutrophil to lymphocyte ratio (NLR) in urothelial cancer: a systematic review. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2016.04.008 CrossRefPubMed

43.

Viers BR, Boorjian SA, Frank I et al (2014) Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol 66:1157–1164. https://doi.org/10.1016/j.eururo.2014.02.042 CrossRefPubMed

44.

Galdiero MR, Bonavita E, Barajon I et al (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218:1402–1410. https://doi.org/10.1016/j.imbio.2013.06.003 CrossRefPubMed

45.

Kruger P, Saffarzadeh M, Weber ANR et al (2015) Neutrophils: between host defence, immune modulation, and tissue injury. PLoS Pathog 11:e1004651. https://doi.org/10.1371/journal.ppat.1004651 CrossRefPubMedPubMedCentral

46.

Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531. https://doi.org/10.1038/nri3024 CrossRefPubMed

47.

Fridlender ZG, Sun J, Kim S et al (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16:183–194. https://doi.org/10.1016/j.ccr.2009.06.017 CrossRefPubMedPubMedCentral

48.

Elinav E, Nowarski R, Thaiss CA et al (2013) Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13:759–771. https://doi.org/10.1038/nrc3611 CrossRefPubMed

49.

Martha O, Porav-Hodade D, Bălan D et al (2017) Easily available blood test neutrophil-to-lymphocyte ratio predicts progression in high-risk non-muscle invasive bladder cancer. Rev Romana Med Lab 25:181–189. https://doi.org/10.1515/rrlm-2017-0016 CrossRef

50.

Shariat SF, Zippe C, Lüdecke G et al (2005) Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173:1518–1525. https://doi.org/10.1097/01.ju.0000154696.48217.75 CrossRefPubMed

Title: Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients
Authors: Mihai Dorin Vartolomei
Shoji Kimura
Matteo Ferro
Liliana Vartolomei
Beat Foerster
Mohammad Abufaraj
Shahrokh F. Shariat
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 7/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2235-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients

Abstract

Background

Materials and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2018

Mesenchymal stem cells inhibit hypoxia-induced inflammatory and fibrotic pathways in bladder smooth muscle cells

Reflections on personalized management of UTUC

Is mini-percutaneous nephrolithotomy a safe alternative to extracorporeal shockwave lithotripsy in pediatric age group in borderline stones? a randomized prospective study

Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs. bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction: 1-year follow-up results

Quality of leadership in multidisciplinary cancer tumor boards: development and evaluation of a leadership assessment instrument (ATLAS)

Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience